NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results

• The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.
• Nektar stated that patients receiving monthly and quarterly dosing regimens resulted in sustained disease control for EASI-75, EASI-90, and other indicators.
• The company also noted that it observed an increase in patients who achieved EASI-100 in the 24 micrograms per kilogram dosing regimens in the monthly and quarterly time periods.

Nektar Therapeutics Inc. (NKTR) shares rose more than 42% in Tuesday’s opening trade after the company reported positive results from its long-term atopic dermatitis trial.

Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.

Retail sentiment around Nektar Therapeutics trended in the ‘extremely bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels. The NKTR stock was among the top ten trending tickers on the platform.

Nektar’s Findings In The Trial

The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.

Nektar stated that patients receiving monthly and quarterly dosing regimens achieved sustained disease control as measured by EASI-75, EASI-90, the validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) response, and the Itch Numerical Rating Scale (NRS) response.

The company also noted an increase in patients achieving EASI-100 on the 24 micrograms per kilogram dosing regimens during the monthly and quarterly periods.

EASI refers to the Eczema Area and Severity Index. It quantifies the severity and extent of eczema symptoms across body regions. EASI-75 points to a greater than or equal to 75% improvement from baseline, while EASI-90 refers to a 90% or more improvement. Similarly, EASI 100 denotes a 100% improvement over baseline.

Retail Gives A Thumbs Up

One bullish user observed that “patience does pay off,” while adding that they are not selling the stock.

Another user stated that there is nothing to “even remotely” criticize Nektar for, following the announcement of the trial results.

NKTR stock is up 24% year-to-date and 204% over the past 12 months.

Also See: Why Is FISV Stock Falling Today?

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on